J Korean Soc Ther Radiol Oncol.  2001 Dec;19(4):345-352.

Radiotherapy Results in Stage IIB Uterine Cervix Cancer

• Kil WJ
• Chun M
• Kang S
• Oh YT
• Ryu HS
• Ju HJ
• Lee EJ

Abstract

PURPOSE: To evaluate the treatment results and prognostic factors after radiotherapy in stage IIB uterine cervix cancer.
MATERIALS AND METHODS
We retrospectively analyzed the records of 90 patients with stage IIB uterine cervix cancer who received radiotherapy between 9/94 and 12/99. Age was ranged from 28 to 79 years (median 57). Tumor size was > or = 4 cm in 64 patients. Preteatment SCC level was measured in 76 patients. Twenty nine patients received conventional radiotherapy (QD) and the others received modified hyperfractionated radiotherapy (BID). Only 7 patients in BID had tumor size <4 cm. All patients received high dose rate brachytherapy (4 Gy x 7 or 5 Gy x 6). No patient received concurrent chemotherapy during radiotherapy. Follow up period was ranging from 9 to 76 months (median 38).
RESULTS
The 5-year overall and disease free survival rates were 73.4% and 71.6%, respectively. Local recurrences occurred in 10% of patients, and distant metastasis in 18.9%. There was a significant correlation between OS/DFS and tumor size (<4 cm; OS 95.2%, DFS 91.4%, > or = 4 cm; OS 63.4%, DFS 63.4%). Pretreatment SCC level was one of prognostic factors only in univariate analysis.
CONCLUSION
With modified hyperfractionated radiotherapy, there was very low local recurrence rate (6.6%) and high 5-year overall and disease free survival rate (75.4% and 70.5%), which is comparable to results after concurrent chemoradiotherapy in bulky, locally advanced stage IIB uterine cervix cancer.

MeSH Terms

Brachytherapy
Cervix Uteri*
Chemoradiotherapy
Disease-Free Survival
Drug Therapy
Female
Follow-Up Studies
Humans
Neoplasm Metastasis
Radiotherapy*
Recurrence
Retrospective Studies